Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer
Executive Summary
The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to co-promote in the US and build commercial infrastructure.